(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-[(2R)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.0^{4,9}]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone

• ChemBase编号: 72473
• 分子式: C51H79NO13
• 平均质量: 914.17186
• 单一同位素质量: 913.55514159
• SMILES: [C@@H]1([C@@H](C[C@@H](CC1)C[C@H]([C@@H]1CC(=O)[C@@H](/C=C(\C)/[C@H]([C@H](C(=O)[C@@H](C[C@@H](/C=C/C=C/C=C(/[C@H](C[C@@H]2CC[C@H]([C@](C(=O)C(=O)N3[C@H](C(=O)O1)CCCC3)(O2)O)C)OC)\C)C)C)OC)O)C)C)OC)O
• Canonical SMILES: CO[C@@H]1C[C@@H](CC[C@H]1O)C[C@H]([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H](CC[C@H]2C)C[C@H](OC)/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C1)C)/C)O)OC)C)C)/C)C
• InChI: InChI=1S/C51H79NO13/c1-30-16-12-11-13-17-31(2)42(61-8)28-38-21-19-36(7)51(60,65-38)48(57)49(58)52-23-15-14-18-39(52)50(59)64-43(33(4)26-37-20-22-40(53)44(27-37)62-9)29-41(54)32(3)25-35(6)46(56)47(63-10)45(55)34(5)24-30/h11-13,16-17,25,30,32-34,36-40,42-44,46-47,53,56,60H,14-15,18-24,26-29H2,1-10H3/b13-11+,16-12+,31-17+,35-25+/t30-,32-,33-,34-,36-,37+,38+,39+,40-,42+,43+,44-,46-,47+,51-/m1/s1
• InChIKey: QFJCIRLUMZQUOT-HPLJOQBZSA-N

名称和登记号

名称

• IUPAC标准名: (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-[(2R)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.0^{4,9}]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone
• IUPAC传统名: SLM
• 别名: Sirolimus; Rapamune; Rapamycin(Sirolimus)

登记号

• CAS号: 53123-88-9
• PubChem SID: 162037398
• PubChem CID: 5284616

理论计算性质

• Acid pKa: 9.963728
• 质子受体: 12
• 质子供体: 3
• LogD (pH = 5.5): 7.4508247
• LogD (pH = 7.4): 7.4496565
• Log P: 7.45084
• 摩尔折射率: 250.6632 cm^3
• 极化性: 97.655174 Å^3
• 极化表面积: 195.43 Å^2
• 可自由旋转的化学键: 6
• 里宾斯基五规则: false

分子性质

理化性质

• 溶解度: DMSO

安全信息

• 保存条件: -20°C

药理学性质

• 作用靶点: mTOR

产品相关信息

• 成盐信息: Free Base

详细说明

Selleck Chemicals - S1039

Research Area

• Description: Immunology

Protocol

• Protocol: Kinase Assay ^[1]
• Immunoblotting for the mTOR kinase assay: HEK293 cells are plated at 2-2.5×10^5 cells/well of a 12-well plate and serum-starved for 24 hours in DMEM. Cells are treated with increasing concentrations of Rapamycin (0.05-50 nM) for 15 minutes at 37 °C. Serum is added to a final concentration of 20% for 30 minutes at 37 °C. Cells are lysed, and cell lysates are separated by SDS-PAGE. Resolved proteins are transferred to a polyvinylidene difluoride membrane and immunoblotted with a phosphospecific primary antibody against Thr-389 of p70 S6 kinase. Data are analyzed using ImageQuant and KaleidaGraph.
• Protocol: Cell Assay ^[3]
• Cell Lines: U87-MG, T98G, and U373-MG
• Concentrations: Dissolved in DMSO, final concentrations ~25 μM
• Incubation Time: 72 hours
• Methods:

  Cells are exposed to various concentrations of Rapamycin for 72 hours. For the assessment of cell viability, cells are collected by trypsinization, stained with trypan blue, and the viable cells in each well are counted. For the determination of cell cycle, cells are trypsinized, fixed with 70% ethanol, and stained with propidium iodide using a flow cytometry reagent set. Samples are analyzed for DNA content using a FACScan flow cytometer and CellQuest software. For apoptosis detection, cells are stained with the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) technique using an ApopTag apoptosis detection kit. To detect the development of acidic vesicular organelles (AVO), cells are stained with acridine orange (1 μg/mL) for 15 minutes, and examined under a fluorescence microscope. To quantify the development of AVOs, cells are stained with acridine orange (1 μg/mL) for 15 minutes, removed from the plate with trypsin-EDTA, and analyzed using the FACScan flow cytometer and CellQuest software. To analyze the autophagic process, cells are incubated for 10 minutes with 0.05 mM monodansylcadaverine at 37 °C and are then observed under a fluorescence microscope.

• Protocol: Animal Study ^[7]
• Animal Models: Athymic Nu/Nu mice inoculated subcutaneously with VEGF-A-expressing C6 rat glioma cells
• Formulation: Dissolved in solvent solution (0.2% carboxymethylcellulose and 0.25% Tween-80 in sterile H2O)
• Doses: ~4 mg/kg/day
• Administration: Injection i.p.

References

• References: [1] Edwards SR, et al. J Biol Chem, 2007, 282(18), 13395-13401.
• References: [2] Barbet NC, et al. Mol Biol Cell, 1996, 7(1), 25-42.
• References: [3] Takeuchi H, et al. Cancer Res, 2005, 65(8), 3336-3346.
• References: [4] Bodine SC, et al. Nat Cell Biol, 2001, 3(11), 1014-1019.
• References: [5] Kenerson HL, et al. Cancer Res, 2002, 62(20), 5645-5650.
• References: [6] Guba M, et al. Nat Med, 2002, 8(2), 128-135.
• References: [7] Phung TL, et al. Cancer Cell, 2006, 10(2), 159-170.

参考文献

• Edwards SR, et al. J Biol Chem, 2007, 282(18), 13395-13401.
• Barbet NC, et al. Mol Biol Cell, 1996, 7(1), 25-42.
• Takeuchi H, et al. Cancer Res, 2005, 65(8), 3336-3346.
• Bodine SC, et al. Nat Cell Biol, 2001, 3(11), 1014-1019.
• Kenerson HL, et al. Cancer Res, 2002, 62(20), 5645-5650.
• Guba M, et al. Nat Med, 2002, 8(2), 128-135.
• Phung TL, et al. Cancer Cell, 2006, 10(2), 159-170.